Bionovo Announces Publication of Bezielle™ Effect on Metabolic Fluxes in Breast Cancer

Bionovo, Inc. BNVI today announced the publication of a study of the metabolic effects of its drug candidate, Bezielle, on cancer cells in the International Journal of Cancer. "This study confirms and expands our earlier understanding of the mechanism of Bezielle cell killing effect," said Uwe Christians, MD, PhD, Professor, iC42 Integrated Solutions in Systems Biology for Clinical Research and Development, University of Colorado, Denver and Bionovo scientific advisory board member. "Bezielle demonstrates incredible selectivity in killing cancer cells while sparing normal cells. It does this by perturbing oxygen metabolism in the cells, from which normal cells can recover, while cancer cells cannot. Using a combined proteomic and metabolomic approach we discovered and confirmed which proteins and enzymes coordinate this selective activity in breast cancer."